Evidence map›Paper›PMID 40057461›Full record

ArticleThe journal of prevention of Alzheimer's disease2025

Machine learning to detect Alzheimer's disease with data on drugs and diagnoses.

Johanna Wallensten, Caroline Wachtler, Nenad Bogdanovic, Anna Olofsson, Miia Kivipelto, Linus Jönsson, Predrag Petrovic, Axel C Carlsson

Abstract read
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Johanna WallenstenDepartment of Clinical Sciences, Danderyd Hospital, 18288, Stockholm, Sweden; Academic Primary Health Care Centre, Region Stockholm, Sweden. Electronic address: johanna.wallensten@ki.se.
Caroline WachtlerAcademic Primary Health Care Centre, Region Stockholm, Sweden; Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Alfred Nobels allé 23, 14183 Huddinge, Sweden. Electronic address: caroline.wachtler@ki.se.
Nenad BogdanovicDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 17177, Stockholm, Sweden. Electronic address: nenad.bogdanovic@ki.se.
Anna OlofssonDivision of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, 17177, Stockholm, Sweden. Electronic address: anna.olofsson.2@ki.se.
Miia KivipeltoDivision of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 17177, Stockholm, Sweden; Theme Inflammation and Aging, Karolinska University Hospital, 17177, Stockholm, Sweden; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, 70211, Kuopio, Finland; Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, SW7 2AZ, United Kingdom. Electronic address: miia.kivipelto@ki.se.
Linus JönssonDepartment of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, 17177, Stockholm, Sweden. Electronic address: linus.jonsson@ki.se.
Predrag PetrovicDepartment of Clinical Neuroscience, Karolinska Institutet, 17177, Stockholm, Sweden; Center for Cognitive and Computational Neurosceince (CCNP), Karolinska Institutet, 17177, Stockholm, Sweden. Electronic address: predrag.petrovic@ki.se.
Axel C CarlssonAcademic Primary Health Care Centre, Region Stockholm, Sweden; Division of Family Medicine and Primary Care, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Alfred Nobels allé 23, 14183 Huddinge, Sweden. Electronic address: axel.carlsson@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntegrating machine learning with medical records offers potential for early detection of Alzheimer's disease (AD), enabling timely interventions.

objectivesThis study aimed to evaluate the effectiveness of machine learning in constructing a predictive model for AD, designed to predict AD with data up to three years before diagnosis. Using clinical data, including prior diagnoses and medical treatments, we sought to enhance sensitivity and specificity in diagnostic procedures. A second aim was to identify the most important factors in the machine learning models, as these may be important predictors of AD.

designThe study employed Stochastic Gradient Boosting, a machine learning method, to identify diagnoses predictive of AD using primary healthcare data. The analyses were stratified by sex and age groups.

settingThe study included individuals within Region Stockholm, Sweden, using medical records from 2010 to 2022.

participantsThe study analyzed clinical data for individuals over the age of 40. Patients with an AD diagnosis (ICD-10-SE codes F00 or G30) during 2010-2012 were excluded to ensure prospective modeling. In total, AD was identified in 3,407 patients aged 41-69 years and 25,796 patients aged over 69. MEASUREMENTS: The machine learning model ranked predictive diagnoses, with performance assessed by the area under the receiver operating characteristic curve (AUC). Known and novel predictors were evaluated for their contribution to AD risk.

resultsAUC values ranged from 0.748 (women aged 41-69) to 0.816 (women over 69), with men across age groups falling within this range. Sensitivity and specificity ranged from 0.73 to 0.79 and 0.66 to 0.79, respectively, across age and gender groups. Negative predictive values were consistently high (≥0.954), while positive predictive values were lower (0.199-0.351). Additionally, we confirmed known risk factors as predictors and identified novel predictors that warrant further investigation. Key predictors included medical observations, cognitive symptoms, antidepressant treatment, visit frequency, and vitamin B12/folic acid treatment.

conclusionsMachine learning applied to clinical data shows promise in predicting AD, with robust model performance across age and sex groups. The findings confirmed known risk factors, such as depression and vitamin B12 deficiency, while also identifying novel predictors that may guide future research. Clinically, this approach could enhance early detection and risk stratification, facilitating timely interventions and improving patient outcomes.

Indexed as

Alzheimer DiseaseMachine LearningAdultAgedAged, 80 and overEarly DiagnosisFemaleHumansMaleMiddle AgedSensitivity and SpecificitySwedenAlzheimer`s diseaseDiagnostic factorsMachine learningPredictive modelPrimary health care

Identifiers

PMID40057461
PMCPMC12184014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.